Publication | Open Access
OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
23
Citations
0
References
2019
Year
MedicineImmunologyPathologyLine TherapyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung Cancer
No additional data available for this publication yet. Check back later!